| Authors: |
Schneider P; ETH Zurich, RETHINK, Department of Chemistry and Applied Biosciences, Zurich, Switzerland., Walters WP; Relay Therapeutics, Cambridge, MA, USA., Plowright AT; Sanofi-Aventis Deutschland GmbH, Integrated Drug Discovery, Frankfurt am Main, Germany., Sieroka N; Institute for Philosophy, University of Bremen, Bremen, Germany., Listgarten J; University of California, Berkeley, Electrical Engineering and Computer Science, Berkeley, CA, USA., Goodnow RA Jr; Pharmaron USA LLC, Boston, MA, USA., Fisher J; Department of Biochemistry, University of Cambridge, Cambridge, UK.; UCL Cancer Institute, University College London, London, UK., Jansen JM; Novartis Institutes for BioMedical Research, Emeryville, CA, USA., Duca JS; Novartis Institutes for BioMedical Research, Cambridge, MA, USA., Rush TS; ATOM Consortium, San Francisco, CA, USA., Zentgraf M; Boehringer Ingelheim Pharma GmbH & Co. KG, Medicinal Chemistry, Biberach an der Riss, Germany., Hill JE; Healthy Life Consultants, New York, NY, USA., Krutoholow E; Bloomberg Intelligence, Bloomberg LP, London, UK., Kohler M; ETH Zurich, Department of Architecture, Zurich, Switzerland., Blaney J; Genentech, 1 DNA Way, South San Francisco, CA, USA., Funatsu K; The University of Tokyo, Department of Chemical System Engineering, Tokyo, Japan.; Nara Institute of Science and Technology, Data Science Center, Nara, Japan., Luebkemann C; ETH Zurich, RETHINK, Department of Chemistry and Applied Biosciences, Zurich, Switzerland.; Arup Global Foresight, San Francisco, CA, USA., Schneider G; ETH Zurich, RETHINK, Department of Chemistry and Applied Biosciences, Zurich, Switzerland. gisbert@ethz.ch. |
